AMAM AMBRX BIOPHARMA INC

Ambrx to Present at Multiple Upcoming Investor Meetings

Ambrx to Present at Multiple Upcoming Investor Meetings

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the TD Cowen Oncology Innovation Summit, the Jefferies Healthcare Conference, and the Goldman Sachs 44th Annual Global Healthcare Conference in the coming weeks. The presentations will focus on the status of Ambrx’s clinical development strategy and an update on the progress of its lead clinical candidates, ARX788 and ARX517.

Presentation details are below:

TD Cowen Oncology Innovation Summit:

Date: Wednesday, May 31st

Time: 1:30pm – 1:55pm ET

Jefferies Healthcare Conference:

Date: Wednesday, June 7

Time: 2:00 – 2:25pm ET

Goldman Sachs 44th Annual Global Healthcare Conference:

Date: Thursday, June 15

Time: 9:20 – 9:50am ET

About Ambrx Biopharma Inc.

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. In addition, Ambrx has preclinical and clinical collaborations with multiple partners on drug candidates generated using Ambrx technology. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology. For more information, please visit . Ambrx routinely posts information that may be important to investors on its website.

Forward-Looking Statements

This press release includes certain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may be identified by the words “intend,” “plan,” and similar expressions. Forward-looking statements are based on Ambrx’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the continuing impact of the COVID-19 pandemic and other public health-related risks and events on Ambrx’s business, operations, strategy, goals and anticipated milestones; Ambrx’s ability to execute on its strategy including with respect to the timing of its R&D efforts, initiation of clinical trials and other anticipated milestones; risks associated with development and marketing approval of novel therapeutics, including potential delays in clinical trials and regulatory submissions and the fact that future clinical trial results/data may not be consistent with interim, initial or preliminary results/data or results/data from prior preclinical studies or clinical trials; Ambrx’s ability to fund operations as anticipated; the satisfaction of closing conditions related to the offering; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Ambrx’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023, and elsewhere in Ambrx’s filings and reports with the SEC, including the prospectus supplement to be filed in connection with the offering. Forward-looking statements contained in this press release are made as of this date, and Ambrx undertakes no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Contacts

INVESTORS

Mike Moyer

LifeSci Advisors

617-308-4306

MEDIA

Mike Tattory

Account Supervisor

LifeSci Communications

609-802-6265

Source: Ambrx Biopharma Inc. 



EN
30/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AMBRX BIOPHARMA INC

 PRESS RELEASE

Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congr...

Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023 In-person event and virtual webcast to be held on Sunday, October 22, 2023 at 8:00pm CEST / 2:00pm ET SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that it will host an in-person key opinion leader (KOL) event during the European Society for Medical Oncology (ESMO) Congress 2023. The event will take place on Sunday, October 22, 2023 from 8:00pm – 10:00pm CEST (2:00pm – 4:00pm ET) at the Santo Mauro Hotel in Madrid, Spain. Discussio...

 PRESS RELEASE

Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Confer...

Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference Morgan Stanley Fireside Chat Replay Now Available SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will participate in a fireside chat and one-on-one meetings at the Cantor Fitzgerald Global Healthcare conference, being held in New York, NY. Presentation details are below: Cantor Fitzgerald Global Healthcare Conference: Date: Wednesday, September 27, 2023Time: 10:20...

 PRESS RELEASE

Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Con...

Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview and participate in one-on-one meetings at the Baird Global Healthcare Conference and the Morgan Stanley 21st Annual Global Healthcare Conference, both being held in New York, NY. The presentations will focus on the status of Ambrx’s lead clinical candidates, ARX788 and ARX517. Prese...

 PRESS RELEASE

Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead ...

Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company’s global regulatory strategy and will report to the Company’s President and Chief Executive Officer, Daniel J. O’Connor. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug devel...

 PRESS RELEASE

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, a...

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023 Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the acceptance of four abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature preliminary safety, efficacy, and pharmacokinetic (PK) dat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch